Nicotine Dependence
Conditions
Keywords
Drugs, Investigational, Therapies for Relapse to Nicotine, Relapse Prevention, Nicotine Cessation Therapies, Smoking Cessation, Nicotine Dependence
Brief summary
The purpose of this study is to evaluate the efficacy of the glycine antagonist, GW468816, compared with placebo on duration of abstinence and rates of relapse in recently quit female smokers in a randomized, double-blind, five-week clinical trial. According to the investigators, the new medication, GW468816, is thought to send certain signals in the brain that may be effective in helping people stay abstinent after they have recently quit smoking. GW468816 is a non-nicotine drug. The investigators of this study hypothesize that subjects receiving GW468816 will demonstrate a significantly longer time to relapse to smoking than those in the placebo group, as measured by the primary outcome measure (see below).
Detailed description
Smoking is the leading cause of preventable mortality in developed countries. Pharmacotherapy, including bupropion and nicotine replacement therapy (NRT), is universally recommended for smoking cessation treatment; however, even with treatment, the majority of smokers either fail to quit in the short term or relapse in the first year. The high failure rate reported for smoking cessation, then, presents a challenge to explore innovative approaches to treating relapse to smoking. The purpose of this study, then, is to evaluate the efficacy of the glycine antagonist, GW468816, compared with placebo on duration of abstinence and rates of relapse in female outpatient smokers during a randomized, double-blind, five-week clinical trial. To do this, the investigators will conduct a two-phase study, in which 300 adult, female outpatient smokers will be enrolled. Phase I will consist of an 8-week smoking cessation study in which nicotine replacement therapy (NRT) and a behavioral intervention are openly administered on a tapered schedule. Participants who are able to quit smoking after 7 weeks in this preliminary study will then be eligible to enter Phase II. Phase II is a 5-week, double-blind, placebo-controlled, relapse prevention trial with the investigational medication, GW468816. Participants in the Phase I smoking cessation study will begin by receiving nicotine replacement therapy in the form of the patch and brief support to stop smoking. Participants will be required to schedule office visits every 1-2 weeks throughout Phase I. Subjects who are abstinent at the end of Phase I will be eligible to continue Phase II, in which they will be randomly assigned by chance to receive the investigational medication, GW468816, at 200 mg or placebo (a pill that looks exactly like the study drug but contains no active drug). Participants will be required to schedule weekly office visits throughout Phase II. Subjects who complete the 15-week trial (both Phases I and II) will enter the 6-Month Follow-Up to evaluate rates of long term abstinence from nicotine. They will have office visits at Weeks 20, 24, 28, 32, 36, and 40 after discontinuation of study medications. Participants who enter the study will be offered the opportunity to participate in an ancillary neuroimaging study of mechanisms and surrogate markers of relapse that includes BOLD fMRI and MR spectroscopy, to be carried out at the McLean Brain Imaging Center.
Interventions
DRUGGW468816
Pharmacotherapies for Relapse Prevention
Sponsors
National Institute on Drug Abuse (NIDA)
Mclean Hospital
GlaxoSmithKline
Massachusetts General Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Written informed consent 2. WOMEN aged 18-65 years, inclusive 3. Self-report of smoking 10 or more cigarettes per day in the past 6 months and expired air CO \>10 ppm at the time of enrollment 4. DSM-IV criteria for current Nicotine Dependence satisfied 5. Subjects must be willing to take the study medication and be motivated to quit smoking (willing to set a quit date within 2 weeks of entry into the protocol) 6. Women of childbearing potential must have a negative urine pregnancy test (quantitative HCG) at baseline and at week 8, prior to receiving the first dose of study medication and females must agree to use an approved form of contraception from the day of the first dose of study medication for 90 days after the last dose of study medication. Approved forms of contraception include any of the following: * Complete abstinence from intercourse from 2 weeks prior to administration of the study drug, through the treatment phase and for 90 days after discontinuation of study medication. * Sterilization of male partner * Implant of levonorgestrel * Injectable progesterone * Intrauterine device (IUD) with \<1 percent rate of failure per year * Any other method with published rate of failure of \<1 percent per year Due to induction of cytochrome p450 3A4, oral contraceptives may be continued during the study but cannot be relied upon as a sole means of contraception, and a second method of contraception such as a barrier method will be required and reimbursed by the study.
Exclusion criteria
1. Pregnant or able to become pregnant and not willing to use approved contraception 2. Severe unstable medical illness including cardiovascular, hepatic, renal, respiratory, metabolic, neurological, or hematological disease by history, physical examination or clinical laboratory test results such that hospitalization for treatment of that illness is likely within the next two months 3. Life-threatening arrhythmia, cerebro-vascular or cardiovascular event within six months of enrollment 4. Elevation over 1.5 times upper limit of normal value (ULN) of any of the following laboratory results: Total, conjugated, or unconjugated bilirubin; alkaline phosphatase, alanine transferase (ALT), aspartate aminotransferase (AST), creatine phosphokinase (CPK), or lactate dehydrogenase (LDH). 5. Use of tobacco-containing products other than cigarettes (e.g., cigar, pipe) 6. Abuse or dependence of any substance other than nicotine or caffeine in the past 6 months. Abuse of alcohol is here defined as an average weekly intake of greater than 21 units or an average daily intake of greater than three units (males) or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than two units (females). One unit is equivalent to a half-pint (220mL) of beer or one (25mL) measure of spirits or one glass (125mL) of wine. 7. Diagnosis of major depressive disorder in the past 6 months 8. Lifetime DSM-IV diagnosis of organic mental disorder, schizophrenia, schizoaffective disorder, bipolar disorder, delusional disorder or psychotic disorders not elsewhere classified 9. History of non-response in the past month to an adequate trial of nicotine re placement therapy, defined as nicotine replacement \> 21 mg per day patch (or equivalent dose of gum, inhaler, nasal spray, or lozenge) for at least 4 weeks. 10. History of multiple adverse drug reactions 11. Use of an investigational drug or device within 4 weeks of enrollment 12. Concurrently enrolled in a study that involves exposure to a drug or device. 13. Urine positive for drugs of abuse at screening visit. 14. Use of statins during the period of the investigation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to Relapse to Smoking in the 5-week Relapse Prevention Phase. | 5 weeks |
| Number of Abstinent and Nonabstinent Participants at End of 5 Week Placebo-controlled Relapse Prevention Trial | 5 weeks |
| Days to Relapse Within the 60 Days Following Randomization | 60 days |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| 816 Group Glycine Antagonist GW468816, 200 mg/day, for a 5-week trial. | 50 |
| Placebo Placebo group for 5 week relapse prevention trial. | 48 |
| Total | 98 |
Baseline characteristics
| Characteristic | Placebo | 816 Group | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 48 Participants | 50 Participants | 98 Participants |
| Age, Continuous | 46.5 years STANDARD_DEVIATION 10.4 | 49.3 years STANDARD_DEVIATION 10.5 | 47.9 years STANDARD_DEVIATION 10.5 |
| Region of Enrollment United States | 48 participants | 50 participants | 98 participants |
| Sex: Female, Male Female | 48 Participants | 50 Participants | 98 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 31 / 50 | 31 / 48 |
| serious Total, serious adverse events | 2 / 50 | 1 / 48 |
Outcome results
Primary
Days to Relapse Within the 60 Days Following Randomization
Time frame: 60 days
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 816 Group | Days to Relapse Within the 60 Days Following Randomization | 20.8 days | Standard Deviation 18.3 |
| Placebo | Days to Relapse Within the 60 Days Following Randomization | 20.6 days | Standard Deviation 20.3 |
Primary
Number of Abstinent and Nonabstinent Participants at End of 5 Week Placebo-controlled Relapse Prevention Trial
Time frame: 5 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| 816 Group | Number of Abstinent and Nonabstinent Participants at End of 5 Week Placebo-controlled Relapse Prevention Trial | 50 participants |
| Placebo | Number of Abstinent and Nonabstinent Participants at End of 5 Week Placebo-controlled Relapse Prevention Trial | 48 participants |
Primary
Time to Relapse to Smoking in the 5-week Relapse Prevention Phase.
Time frame: 5 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| 816 Group | Time to Relapse to Smoking in the 5-week Relapse Prevention Phase. | 14.5 days | Standard Deviation 14 |
| Placebo | Time to Relapse to Smoking in the 5-week Relapse Prevention Phase. | 12.4 days | Standard Deviation 12.5 |